About Prominin-2
Prominin-2 (PROM2) is a protein
from Homo sapiens identified by UniProt accession
Q8N271, 834 residues long.
MolForge cross-references it against 0 known binders and
165 disease associations.
Target properties
| Protein name | Prominin-2 |
|---|
| UniProt accession | Q8N271 |
|---|
| Gene | PROM2 |
|---|
| Organism | Homo sapiens |
|---|
| Length | 834 residues |
|---|
| Molecular weight | — |
|---|
| EC numbers | — |
|---|
| Target class | UNCLASSIFIED |
|---|
| Subcellular location | — |
|---|
| Keywords | — |
|---|
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
|---|
| Druggability score | — |
|---|
| Pocket score | — |
|---|
| Max clinical phase | — |
|---|
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
|---|
| AF-Q8N271-F1 | alphafold | PREDICTED | 85.82 | — |
Amino-acid sequence (834 residues)
MKHTLALLAP LLGLGLGLAL SQLAAGATDC KFLGPAEHLT FTPAARARWL APRVRAPGLL DSLYGTVRRF LSVVQLNPFP SELVKALLNE LASVKVNEVV RYEAGYVVCA VIAGLYLLLV PTAGLCFCCC RCHRRCGGRV KTEHKALACE RAALMVFLLL TTLLLLIGVV CAFVTNQRTH EQMGPSIEAM PETLLSLWGL VSDVPQELQA VAQQFSLPQE QVSEELDGVG VSIGSAIHTQ LRSSVYPLLA AVGSLGQVLQ VSVHHLQTLN ATVVELQAGQ QDLEPAIREH RDRLLELLQE ARCQGDCAGA LSWARTLELG ADFSQVPSVD HVLHQLKGVP EANFSSMVQE ENSTFNALPA LAAMQTSSVV QELKKAVAQQ PEGVRTLAEG FPGLEAASRW AQALQEVEES SRPYLQEVQR YETYRWIVGC VLCSVVLFVV LCNLLGLNLG IWGLSARDDP SHPEAKGEAG ARFLMAGVGL SFLFAAPLIL LVFATFLVGG NVQTLVCQSW ENGELFEFAD TPGNLPPSMN LSQLLGLRKN ISIHQAYQQC KEGAALWTVL QLNDSYDLEE HLDINQYTNK LRQELQSLKV DTQSLDLLSS AARRDLEALQ SSGLQRIHYP DFLVQIQRPV VKTSMEQLAQ ELQGLAQAQD NSVLGQRLQE EAQGLRNLHQ EKVVPQQSLV AKLNLSVRAL ESSAPNLQLE TSDVLANVTY LKGELPAWAA RILRNVSECF LAREMGYFSQ YVAWVREEVT QRIATCQPLS GALDNSRVIL CDMMADPWNA FWFCLAWCTF FLIPSIIFAV KTSKYFRPIR KRLSSTSSEE TQLFHIPRVT SLKL
Explore Prominin-2 with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets